CD45 isoform expression in autoimmune myasthenia gravis

B Tackenberg1, M Nitschke, N Willcox

  • 1Department of Neurology, Philipps-University, Rudolf-Bultmann Street 8, D-35033 Marburg, Germany.

Autoimmunity
|June 25, 2003
PubMed

Insights

This study found no link between a specific CD45 gene mutation and myasthenia gravis (MG). However, late-onset MG patients showed altered T cell subsets, suggesting a different immune balance in this condition.

Area of Science:

  • Immunology
  • Genetics
  • Neurology

Background:

  • Myasthenia gravis (MG) involves complex immune system dysregulation.
  • The CD45 molecule (protein-tyrosine phosphatase receptor type C, PTPRC) plays a critical role in T and B cell function.
  • Previous research suggested a CD45 association in multiple sclerosis.

Purpose of the Study:

  • To investigate the role of the CD45 molecule in myasthenia gravis pathogenesis.
  • To determine the prevalence of a specific CD45 gene mutation (exon 4 77C --> G) in MG patients.
  • To analyze the distribution of naive (CD45RA+) and memory (CD45RO+) T cells in MG patients' peripheral blood.

Main Methods:

  • Flow cytometry was used to quantify CD45RA+ and CD45RO+ T cells in 78 generalized MG patients and 67 age/sex-matched controls.
  • Prevalence analysis of the CD45 gene mutation involved 78 MG patients and 303 healthy individuals.
  • Statistical analyses included Fisher's exact test, chi-squared test, Mann-Whitney test, and Spearman's correlation.

Main Results:

  • The 77C --> G mutation in CD45 exon 4 was found in one MG patient but not in 303 controls, indicating no overall association.
  • A significantly lower ratio of CD45RO+ to CD45RA+ T cells was observed in CD8+ T cells of late-onset MG patients (P = 0.023).
  • A similar trend was noted in CD4+ and CD8+ T cells of thymoma patients, independent of treatment or thymectomy.

Conclusions:

  • The specific CD45 gene mutation studied is not associated with myasthenia gravis.
  • Late-onset MG patients exhibit an altered balance of circulating T cell subsets.
  • This altered subset distribution may reflect a distinct immunological profile in late-onset MG, potentially independent of thymopoiesis.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Chemical Synapses01:26

Chemical Synapses

Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...